Aarti Pharmalabs: The financial results for the period ended September 30, 2026
Aarti Pharmalabs (AARTIPHARM) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹7,998 crore.
What happened
Aarti Pharmalabs (AARTIPHARM) filed a disclosure with the exchanges on 28 October 2026 at 09:02 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Aarti Pharmalabs is a small-cap company in the Healthcare sector, with a market value of about ₹7,998 crore.
The stock last traded at ₹882, against a 52-week range of ₹585–₹1,002.4 (12.0% below the high).
Before this filing the shares had moved −12.4% over the month and +20.3% over three months. Average daily turnover over the last 20 sessions was about ₹51.81 crore.
Promoters held 42.86% at the end of Q1 FY27, down 0.22% points from the previous quarter; 11.08% of promoter shares were pledged. Foreign institutions owned 8.17% and domestic institutions 7.22%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 386 | 49.5 | 5.46 |
| Q2 FY26 | 418 | 28.6 | 3.08 |
| Q3 FY26 | 432 | 46.4 | 5.29 |
| Q4 FY26 | 583 | 61.1 | 6.74 |
| Q1 FY27 | 536 | 76.1 | 8.4 |
What history shows
This is not the company's first results disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 2.6% on average the next trading day and was down 0.3% on average after five days (3 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +1.7% over five days; 54% of them rose the next day.
Market-wide, 9,836 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 7 Aug 2026 | Approval Of Unaudited Financial Results (Standalone And… | +28.8% | +25.7% |
| 26 May 2026 | Audited Financial Results For The Quarter And Financial Year Ended… | −10.5% | −13.3% |
| 25 May 2026 | Board Meeting Outcome for Approval Of Audited Standalone And… | −10.5% | −13.3% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 28 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Aarti Pharmalabs revamps website to enhance digital accessibility
- AARTI PHARMALABS LIMITED (AARTIPHARM.NS) Q3 25/26 earnings call transcript
- Aarti Pharmalabs (NSEI:AARTIPHARM) - Stock Analysis
- Aarti Pharmalabs Slips 4.73% to ₹832.35 as Sellers Test the ₹790.73 Support Zone - Virgin POC
- Aarti Pharmalabs Q2 consolidated net profit up 170% to ₹754 crore
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.